15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Protara Therapeutics Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $24.00 to $28.00, so the covering firms are broadly aligned. The average target of $26.25 sits 565% above the current $3.95. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.33 next quarter toward $-1.64 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Protara Therapeutics Inc.
As of Jul, 4 of 4 firms rate TARA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
TARA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.33
Range $-0.38 – $-0.26 · 7 analysts · +7% YoY
Next period, 7 analysts expect Protara Therapeutics Inc to earn $-0.33 a share (range $-0.38 – $-0.26), versus $-0.31 a year earlier. Full-year consensus is $-1.39, growing to $-1.64 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.0M next year.
Top analysts covering Protara Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TARA.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$20.00+406.3% to target
Overall win rate
55%
+ Follow
#2
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$27.00+583.5% to target
Overall win rate
46%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$23.00+482.3% to target
Overall win rate
38%
+ Follow
#4
Li Watsek
Cantor Fitzgerald · Rank #218
Buy
No targeton TARA
Overall win rate
38%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #254
Buy
$28.00+608.9% to target
Overall win rate
37%
+ Follow
TARA stock forecast FAQ
What is TARA's average 12-month price target?+
The 4 analysts with a live target average $26.25 for Protara Therapeutics Inc over the next 12 months, ranging from a $28.00 high to a $24.00 low.
Is TARA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for TARA?+
The Street-high target is $28.00 (Oppenheimer), and the Street-low is $24.00 (Piper Sandler). The average of all 4 active targets is $26.25.
How many Wall Street analysts cover TARA?+
4 analysts have an active rating on Protara Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering TARA?+
Among analysts who currently cover TARA, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $20.00 target.
What is Protara Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.33 per share (range $-0.38 – $-0.26) across 7 analysts. Full-year EPS is projected at $-1.39, rising to $-1.64 the following year.
How much revenue is Protara Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.0M next year.
Have analysts been upgrading or downgrading TARA lately?+
As of Jul, 4 of 4 firms rate TARA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TARA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
